Age-Related Disorder

Lowe, Derek B.
January 2013
Contract Pharma;Jan/Feb2013, Vol. 15 Issue 1, p30
Trade Publication
The article focuses on disorders associated to aging and the discovery of drugs for these diseases by pharmaceutical companies in the U.S. It notes the scrutiny whether a drugmaker intends to sell medication for unapproved uses. It considers the ability of the Food and Drug Administration (FDA) to gather appropriate evidence as improbable since it opts for egregious instances. It points out the privilege of drugmakers to market their medicines.


Related Articles

  • Will medications be safer in the future? Erickson, Amy K. // Pharmacy Today;Nov2010, Vol. 16 Issue 11, p40 

    The article focuses on issues faced by the U.S. Food and Drug Administration (FDA) concerning safety and quality of drugs manufactured abroad. It highlights on the regulatory system implemented by FDA to ensure that products made outside the U.S. meet the standards of the pharmaceutical...

  • The Metrics of Quality Culture. Harrison, Andrew; Schniepp, Susan // Pharmaceutical Technology;Sep2015, Vol. 39 Issue 9, p22 

    The article discusses the guidance for quality metrics proposed by the U.S Food & Drug Administration (USFDA). Topics discussed include passage of the Food and Drug Administration Safety and Innovation Act (FDASIA) to prevent drug shortage, use of the guidance by pharmaceutical industries to...

  • Understanding ICH Q11--FDA's Guidance on the Development and Manufacture of Drug Substances. Mehta, Bob // Pharmaceutical Technology Europe;May2013, Vol. 25 Issue 5, p57 

    In this article, the author provides a review of Q11 Development and Manufacture of Drug Substances, a guidance document for pharmaceutical industry issued by the U.S. Food and Drug Administration (FDA). He discusses the relation of the guidance document with the international Conference on...

  • Drug shortages on the decline. DeBenedette, Valerie // Drug Topics;Aug2015, Vol. 159 Issue 8, p28s 

    The article reports on the declining rate of unavailable drugs and drugs that lack supply in the U.S. Topics covered include Food and Drug Administration (FDA) reports on shortage of 251 drugs in 2011 down to a shortage of 44 drugs in 2014, 30 of which are injectables that has affected health...

  • Pipeline 2011. Perry, Leah E. // Drug Topics;Jan2011, Vol. 155 Issue 1, p30 

    The article offers forecasts on the trends in the pharmaceutical industry for 2011 in the U.S. It reveals that drug development has continued to drop compared to the successful period in previous years. It also shows the slow-moving rate at which the Food and Drug Administration (FDA) approves...

  • Companion Prospecting. Agres, Ted // Drug Discovery & Development;Sep2011, Vol. 14 Issue 9, p10 

    The article focuses on the effort of the U.S. Food and Drug Administration (FDA) to start companion diagnostics despite scientific, logistical, and financial barriers. It asserts that companion diagnostics hold great promise for gaining ground personalized medicine permitting drug developers to...

  • Biosimilar Guidances Issued. Wechsler, Jill // Applied Clinical Trials;Mar2012, Vol. 21 Issue 3, p18 

    The article reports on guidances issued by the U.S. Food and Drug Administration (FDA) in February 2012. It relates that these guidances outline FDA's recommendations for developing and approving biosimilar therapies. Moreover, they map out the scientific considerations, quality analytical...

  • The Validation Master Plan. Chatterjee, Bikash // Pharmaceutical Processing;Sep2011, Vol. 26 Issue 8, p14 

    The article describes the validation master plan (VMP) and three stages of the U.S. Food and Drug Administration's (FDA) new process validation guidance for pharmaceutical processing. It discusses the three stages of the process validation guidance including process design, process qualification...

  • QbD Gains Momentum. Bush, Laura // BioPharm International;Feb2010, Vol. 23 Issue 2, p10 

    The article offers updates on Quality by Design (QbD) which was adopted by the U.S. Food and Drug Administration. It is noted that Qbd has shown a significant progress and its aspects has gain confidence from the pharmaceutical industry, particularly the process development of the QbD framework....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics